Home » Newsletters » BioWorld Science

BioWorld Science

April 12, 2011

View Archived Issues

New PET tracer BAY-94-9392 distinguishes tumors from inflammation in vivo; phase I trials ongoing

Alisporivir enhances efficacy of standard care in patients with hepatitis C

High-dose once-weekly rosuvastatin shows comparable safety/efficacy to standard daily atorvastatin

Phase I and II data reported on hepatitis C treatment BI-201335

Roche discloses preclinical findings on new farnesoid X receptor agonists

Astellas evaluates selective GlyT1 inhibitor AS-1522489-00 for psychiatric disorders

Endo Pharmaceuticals to acquire American Medical Systems

Kyorin releases new Uritos formulation in Japan for overactive bladder

Pfizer to supply Sutent for immatics' phase III IMA-901 trial in advanced renal cell cancer

Sumitomo Chemical designs new inhibitors of 17-beta-HSD 3

DMC recommends suspending enrollment in phase II/III trial of V-710

Roche designs new inhibitors of HCV NS5B

New negative allosteric modulators of metabotropic glutamate mGlu5 receptor claimed

Ferring presents new oxytocin OT receptor agonists

Dainippon Sumitomo Pharma claims new inhibitors of fatty-acid amide hydrolase

Invega obtains FDA approval for treatment of schizophrenia in adolescents

Vertex Pharma and CFFT expand cystic fibrosis drug discovery collaboration

Cytogel Pharma reports phase I data on CYT-1010 for pain

Pfizer and Medivation report phase III data on Dimebon in Huntington's disease

PROLOR reports promising phase II results on hGH-CTP in growth hormone deficiency

Phase II trial of Eladur transdermal bupivacaine pain patch does not meet primary endpoint

FDA allows marketing of first diagnostic test for dengue fever

Verona Pharma begins phase II trial of RPL-554 in COPD

GW Pharma and Novartis sign license agreement for commercialization of Sativex in multiple regions

FDA approves Sylatron for injection as adjuvant treatment for melanoma

Almirall discovers new chemical entity for COPD

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...